| Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? N Hosseinkhani, A Derakhshani, O Kooshkaki, M Abdoli Shadbad, ... International Journal of Molecular Sciences 21 (21), 8305, 2020 | 84 | 2020 |
| Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in triple-negative breast cancer (TNBC): a … P Lotfinejad, M Asghari Jafarabadi, M Abdoli Shadbad, T Kazemi, ... Diagnostics 10 (9), 704, 2020 | 80 | 2020 |
| Recent developments of RNA-based vaccines in cancer immunotherapy E Faghfuri, F Pourfarzi, AH Faghfouri, M Abdoli Shadbad, ... Expert Opinion on Biological Therapy 21 (2), 201-218, 2021 | 77 | 2021 |
| Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine A Derakhshani, S Hashemzadeh, Z Asadzadeh, MA Shadbad, ... Cancers 13 (10), 2414, 2021 | 68 | 2021 |
| The role of CD44 in cancer chemoresistance: A concise review Z Yaghobi, A Movassaghpour, M Talebi, MA Shadbad, ... European Journal of Pharmacology 903, 174147, 2021 | 63 | 2021 |
| The oncogenic potential of NANOG: An important cancer induction mediator B Najafzadeh, Z Asadzadeh, R Motafakker Azad, A Mokhtarzadeh, ... Journal of Cellular Physiology 236 (4), 2443-2458, 2021 | 52 | 2021 |
| Arginase 1 (Arg1) as an Up-Regulated Gene in COVID-19 Patients: A Promising Marker in COVID-19 Immunopathy A Derakhshani, N Hemmat, Z Asadzadeh, M Ghaseminia, MA Shadbad, ... Journal of Clinical Medicine 10 (5), 1051, 2021 | 51 | 2021 |
| Interleukin-1 in obesity-related low-grade inflammation: From molecular mechanisms to therapeutic strategies M Ghanbari, SM Maragheh, A Aghazadeh, SR Mehrjuyan, BM Hussen, ... International Immunopharmacology 96, 107765, 2021 | 46 | 2021 |
| The role of V-domain Ig suppressor of T cell activation (VISTA) in cancer therapy: lessons learned and the road ahead N Hosseinkhani, A Derakhshani, MA Shadbad, A Argentiero, V Racanelli, ... Frontiers in Immunology 12, 676181, 2021 | 43 | 2021 |
| A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery MA Shadbad, S Safaei, O Brunetti, A Derakhshani, P Lotfinejad, ... Genes 12 (8), 1206, 2021 | 37 | 2021 |
| From Oncogenic Signaling Pathways to Single-Cell Sequencing of Immune Cells: Changing the Landscape of Cancer Immunotherapy A Derakhshani, Z Rostami, H Safarpour, MA Shadbad, NS Nourbakhsh, ... Molecules 26 (8), 2278, 2021 | 37 | 2021 |
| Regulation of immune responses through CD39 and CD73 in cancer: novel checkpoints E Baghbani, S Noorolyai, D Shanehbandi, A Mokhtarzadeh, ... Life Sciences 282, 119826, 2021 | 35 | 2021 |
| PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines P Lotfinejad, T Kazemi, S Safaei, M Amini, E Baghbani, SS Shotorbani, ... Biomedicine & Pharmacotherapy 138, 111436, 2021 | 33 | 2021 |
| Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFNβ-1α, Glatiramer Acetate, and Dimethyl Fumarate … A Derakhshani, Z Asadzadeh, H Safarpour, P Leone, MA Shadbad, ... Journal of Personalized Medicine 11 (8), 721, 2021 | 23 | 2021 |
| From melanoma development to RNA-modified dendritic cell vaccines: highlighting the lessons from the past MA Shadbad, K Hajiasgharzadeh, A Derakhshani, N Silvestris, ... Frontiers in Immunology 12, 623639, 2021 | 23 | 2021 |
| siRNA-mediated silencing of CD44 delivered by Jet Pei enhanced Doxorubicin chemo sensitivity and altered miRNA expression in human breast cancer cell line (MDA-MB468) F Vahidian, E Safarzadeh, A Mohammadi, S Najjary, B Mansoori, J Majidi, ... Molecular Biology Reports 47, 9541-9551, 2020 | 23 | 2020 |
| Cross-talk between myeloid-derived suppressor cells and Mucin1 in breast cancer vaccination: On the verge of a breakthrough MA Shadbad, K Hajiasgharzadeh, B Baradaran Life Sciences 258, 118128, 2020 | 23 | 2020 |
| A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery MA Shadbad, Z Asadzadeh, A Derakhshani, N Hosseinkhani, ... Biomedicine & Pharmacotherapy 143, 112213, 2021 | 22 | 2021 |
| Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside F Ghorbaninezhad, Z Asadzadeh, J Masoumi, A Mokhtarzadeh, T Kazemi, ... Life Sciences 297, 120466, 2022 | 21 | 2022 |
| The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy A Baradaran, Z Asadzadeh, N Hemmat, A Baghbanzadeh, MA Shadbad, ... Biomedicine & Pharmacotherapy 146, 112588, 2022 | 21 | 2022 |
behzad baradaranImmunology Research Center, Tabriz University of Medical Sciences在 tbzmed.ac.ir 的电子邮件经过验证
